share_log

华海药业(600521.SH):恩格列净片获得药品注册证书

Huahai Pharmaceutical (600521.SH): Empagliflozin tablets obtained drug registration certificate

Gelonghui Finance ·  Apr 15 05:20

Gelonghui, April 15, 丨 Huahai Pharmaceutical (600521.SH) announced that it has recently received the “Drug Registration Certificate” for englicin tablets approved and issued by the State Drug Administration. Engagliptin tablets are used to treat adult patients with type 2 diabetes and heart failure.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment